R Klamroth

Summary

Country: Germany

Publications

  1. doi request reprint Successful angiographic embolization of recurrent elbow and knee joint bleeds in seven patients with severe haemophilia
    R Klamroth
    Department of Angiology and Clotting disorders, Haemophilia Treatment Center, Vivantes Klinikum im Friedrichshain, Berlin, Germany
    Haemophilia 15:247-52. 2009
  2. ncbi request reprint A new era of treatment for patients with haemophilia A?
    Robert Klamroth
    Dr med Robert Klamroth, Zentrum für Hämophilie und Hämostaseologie, Vivantes Netzwerk für Gesundheit, Landsberger Alle 49, 10249 Berlin, Germany, Tel 49 30 130231623 Fax 49 30 130231313, E mail
    Hamostaseologie . 2016
  3. doi request reprint Prospective evaluation of treatment regimens, efficacy and safety of a recombinant factor VIII concentrate in haemophilia A: the German EffeKt study
    R Klamroth
    Abteilung fur Innere Medizin, Vivantes Klinikum Friedrichshain, Berlin, Germany
    Haemophilia 22:684-91. 2016
  4. doi request reprint Long-term efficacy and safety of a pasteurized, plasma-derived factor VIII concentrate (Beriate® P) in patients with haemophilia A
    Robert Klamroth
    Department of Internal Medicine Angiology and Clotting Disorders, Haemophilia Treatment Centre, Vivantes Klinikum im Friedrichshain, Berlin, Germany Electronic address
    Thromb Res 134:S38-42. 2014
  5. doi request reprint [Acquired bleeding disorders - diagnostic approach]
    R Klamroth
    Klinik fur Innere Medizin, Angiologie und Hämostaseologie Hämophiliezentrum, Vivantes Klinikum im Friedrichshain, Landsberger Allee 49, 10249, Berlin, Deutschland
    Internist (Berl) 55:514-20. 2014
  6. doi request reprint The influence of thrombophilic risk factors on vascular access survival in chronic dialysis patients in a retrospective evaluation
    Robert Klamroth
    Department for Internal Medicine, Vivantes Hospital in Friedrichshain, Berlin, Germany
    Vasa 42:32-9. 2013
  7. doi request reprint Bridging with enoxaparin using a half-therapeutic dose regimen: safety and efficacy
    Robert Klamroth
    Klinik fur Innere Medizin, Angiologie Haemostaseologie und Pneumologie, Vivantes Klinikum im Friedrichshain, Berlin, Germany
    Vasa 39:243-8. 2010
  8. ncbi request reprint [Haemophilia A and haemophilia B. Are there relevant clinical differences?]
    R Klamroth
    Klinik für Innere Medizin Angiologie und Hämostaseologie, Vivantes Klinikum im Friedrichshain, Landsberger Allee 49, 10249 Berlin
    Hamostaseologie 30:S26-7. 2010
  9. doi request reprint The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study
    R Klamroth
    Vivantes Klinikum in Friedrichhain, Klinik fuer Innere Medizin, Haemophiliezentrum, Berlin, Germany
    Haemophilia 17:412-21. 2011

Detail Information

Publications9

  1. doi request reprint Successful angiographic embolization of recurrent elbow and knee joint bleeds in seven patients with severe haemophilia
    R Klamroth
    Department of Angiology and Clotting disorders, Haemophilia Treatment Center, Vivantes Klinikum im Friedrichshain, Berlin, Germany
    Haemophilia 15:247-52. 2009
    ....
  2. ncbi request reprint A new era of treatment for patients with haemophilia A?
    Robert Klamroth
    Dr med Robert Klamroth, Zentrum für Hämophilie und Hämostaseologie, Vivantes Netzwerk für Gesundheit, Landsberger Alle 49, 10249 Berlin, Germany, Tel 49 30 130231623 Fax 49 30 130231313, E mail
    Hamostaseologie . 2016
    ..Mimicking the cofactor activity of factor VIII by a bispecific antibody for the treatment of severe haemophilia A is so far safe and seems to be effective and is one highlight in haemostasis 2016...
  3. doi request reprint Prospective evaluation of treatment regimens, efficacy and safety of a recombinant factor VIII concentrate in haemophilia A: the German EffeKt study
    R Klamroth
    Abteilung fur Innere Medizin, Vivantes Klinikum Friedrichshain, Berlin, Germany
    Haemophilia 22:684-91. 2016
    ..Collecting clinical data under routine conditions remains important to monitor continuously efficacy and tolerability of an established product...
  4. doi request reprint Long-term efficacy and safety of a pasteurized, plasma-derived factor VIII concentrate (Beriate® P) in patients with haemophilia A
    Robert Klamroth
    Department of Internal Medicine Angiology and Clotting Disorders, Haemophilia Treatment Centre, Vivantes Klinikum im Friedrichshain, Berlin, Germany Electronic address
    Thromb Res 134:S38-42. 2014
    ..Pathogen safety is achieved by careful donor selection and a combination of pasteurization and chromatographic purification steps...
  5. doi request reprint [Acquired bleeding disorders - diagnostic approach]
    R Klamroth
    Klinik fur Innere Medizin, Angiologie und Hämostaseologie Hämophiliezentrum, Vivantes Klinikum im Friedrichshain, Landsberger Allee 49, 10249, Berlin, Deutschland
    Internist (Berl) 55:514-20. 2014
    ..Patients with acquired bleeding disorders are often a diagnostic challenge in internal medicine...
  6. doi request reprint The influence of thrombophilic risk factors on vascular access survival in chronic dialysis patients in a retrospective evaluation
    Robert Klamroth
    Department for Internal Medicine, Vivantes Hospital in Friedrichshain, Berlin, Germany
    Vasa 42:32-9. 2013
    ..Thrombophilic risk factors are discussed as one cause for occlusion. The aim of this study was to determine if the presence of thrombophilic factors is associated with a reduced survival rate of vascular dialysis access...
  7. doi request reprint Bridging with enoxaparin using a half-therapeutic dose regimen: safety and efficacy
    Robert Klamroth
    Klinik fur Innere Medizin, Angiologie Haemostaseologie und Pneumologie, Vivantes Klinikum im Friedrichshain, Berlin, Germany
    Vasa 39:243-8. 2010
    ..We investigated the efficacy and safety of a standardized bridging therapy with enoxaparin in a half-therapeutic dose in patients with a target INR of 2,0 to 3,0...
  8. ncbi request reprint [Haemophilia A and haemophilia B. Are there relevant clinical differences?]
    R Klamroth
    Klinik für Innere Medizin Angiologie und Hämostaseologie, Vivantes Klinikum im Friedrichshain, Landsberger Allee 49, 10249 Berlin
    Hamostaseologie 30:S26-7. 2010
    ..In comparison to haemophilia A (HA) the bleeding tendency seemed to be less severe. The aim of this study was to investigate this hypothesis in all patients with HA and HB treated in the haemophilia care center of the Vivantes Klinikum...
  9. doi request reprint The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study
    R Klamroth
    Vivantes Klinikum in Friedrichhain, Klinik fuer Innere Medizin, Haemophiliezentrum, Berlin, Germany
    Haemophilia 17:412-21. 2011
    ..Physical, but not mental, HRQOL is diminished in HA patients. Target joints are associated with lower physical HRQOL, although this effect is moderated by age...